Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 266.81% and Operating profit at 3.84% over the last 5 years
3
The company has declared Positive results for the last 4 consecutive quarters
4
Risky -
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,731 Million (Large Cap)
NA (Loss Making)
NA
0.00%
-0.83
-11.93%
14.56
Revenue and Profits:
Net Sales:
218 Million
(Quarterly Results - Sep 2025)
Net Profit:
-20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.06%
0%
-1.06%
6 Months
34.91%
0%
34.91%
1 Year
66.75%
0%
66.75%
2 Years
75.56%
0%
75.56%
3 Years
151.67%
0%
151.67%
4 Years
25.4%
0%
25.4%
5 Years
21.78%
0%
21.78%
Suzhou Zelgen Biopharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
266.81%
EBIT Growth (5y)
3.84%
EBIT to Interest (avg)
-113.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0.21
Tax Ratio
3.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
15.01
EV to EBIT
-70.17
EV to EBITDA
-95.07
EV to Capital Employed
101.80
EV to Sales
25.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-145.08%
ROE (Latest)
-12.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
217.80
143.40
51.88%
Operating Profit (PBDIT) excl Other Income
-38.30
-25.60
-49.61%
Interest
3.40
6.40
-46.88%
Exceptional Items
0.80
0.30
166.67%
Consolidate Net Profit
-20.00
-32.10
37.69%
Operating Profit Margin (Excl OI)
-175.90%
-294.50%
11.86%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 51.88% vs 130.55% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 37.69% vs 65.67% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
532.70
386.20
37.93%
Operating Profit (PBDIT) excl Other Income
-162.70
-348.40
53.30%
Interest
29.10
24.50
18.78%
Exceptional Items
3.90
8.70
-55.17%
Consolidate Net Profit
-150.30
-295.10
49.07%
Operating Profit Margin (Excl OI)
-420.50%
-1,058.40%
63.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 37.93% vs 27.88% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 49.07% vs 39.22% in Dec 2023
About Suzhou Zelgen Biopharmaceuticals Co., Ltd. 
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






